Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP951639.RAEstysOg34TXs3g2yHNFIzphuFN0dOL8Ha5uG2Q4oY-M130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP951639.RAEstysOg34TXs3g2yHNFIzphuFN0dOL8Ha5uG2Q4oY-M130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP951639.RAEstysOg34TXs3g2yHNFIzphuFN0dOL8Ha5uG2Q4oY-M130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP951639.RAEstysOg34TXs3g2yHNFIzphuFN0dOL8Ha5uG2Q4oY-M130_provenance.
- NP951639.RAEstysOg34TXs3g2yHNFIzphuFN0dOL8Ha5uG2Q4oY-M130_assertion description "[Despite patients with FIP1-like-1-platelet-derived growth factor alpha (FIP1L1-PDGFRA) associated HES (myeloid neoplasms associated with PDGFRA rearrangement) have been shown to respond to low-dose imatinib with a complete and durable hematological and cytogenetic remission, influences of imatinib on clinical manifestations related to hypereosinophilia heart involvement are variable.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP951639.RAEstysOg34TXs3g2yHNFIzphuFN0dOL8Ha5uG2Q4oY-M130_provenance.
- NP951639.RAEstysOg34TXs3g2yHNFIzphuFN0dOL8Ha5uG2Q4oY-M130_assertion evidence source_evidence_literature NP951639.RAEstysOg34TXs3g2yHNFIzphuFN0dOL8Ha5uG2Q4oY-M130_provenance.
- NP951639.RAEstysOg34TXs3g2yHNFIzphuFN0dOL8Ha5uG2Q4oY-M130_assertion SIO_000772 19096755 NP951639.RAEstysOg34TXs3g2yHNFIzphuFN0dOL8Ha5uG2Q4oY-M130_provenance.
- NP951639.RAEstysOg34TXs3g2yHNFIzphuFN0dOL8Ha5uG2Q4oY-M130_assertion wasDerivedFrom befree-20150227 NP951639.RAEstysOg34TXs3g2yHNFIzphuFN0dOL8Ha5uG2Q4oY-M130_provenance.
- NP951639.RAEstysOg34TXs3g2yHNFIzphuFN0dOL8Ha5uG2Q4oY-M130_assertion wasGeneratedBy ECO_0000203 NP951639.RAEstysOg34TXs3g2yHNFIzphuFN0dOL8Ha5uG2Q4oY-M130_provenance.
- befree-20150227 importedOn "2015-02-27" NP951639.RAEstysOg34TXs3g2yHNFIzphuFN0dOL8Ha5uG2Q4oY-M130_provenance.